Genetic effects in a progressive model of parkinsonism induced by reserpine

Psychopharmacology (Berl). 2023 May;240(5):1131-1142. doi: 10.1007/s00213-023-06350-6. Epub 2023 Mar 24.

Abstract

Objective and methods: We investigated the locomotor, emotional, physiological, and neurobiological effects induced by low-dose reserpine repeated treatment (0.1 mg/kg; 14 injections) in males from the Lewis (LEW), Spontaneously Hypertensive Rats (SHR), and SHR.LEW-(D4Rat76-D4Mgh11) (SLA16) isogenic rat strains, which have different genetic backgrounds on chromosome 4. Behavioral responses in the catalepsy, open-field, and oral movements' tests were coupled with blood pressure, body weight, and striatal tyrosine hydroxylase (TH) level assessments to establish neurobiological comparisons between reserpine-induced impairments and genetic backgrounds RESULTS: Results revealed the SHR strain was more sensitive in the catalepsy test and exhibited higher TH immunoreactivity in the dorsal striatum. The SLA16 strain presented more oral movements, suggesting increased susceptibility to develop oral dyskinesia.

Conclusions: Our results showed the efficacy of repeated treatment with a low dose of reserpine and demonstrated, for the first time, the genetic influence of a specific region of chromosome 4 on the expression of these effects.

Keywords: Blood pressure; Oral dyskinesia; Parkinson’s disease; SHR; Tyrosine hydroxylase.

MeSH terms

  • Animals
  • Behavior, Animal
  • Catalepsy
  • Male
  • Parkinsonian Disorders* / chemically induced
  • Parkinsonian Disorders* / genetics
  • Parkinsonian Disorders* / metabolism
  • Rats
  • Rats, Inbred Lew
  • Rats, Inbred SHR
  • Reserpine* / toxicity

Substances

  • Reserpine